A multidisciplinary team of University of Cincinnati Cancer Center researchers have opened a Phase 2 clinical trial to test a new combination treatment for glioblastomas (GBM), the most deadly form of brain tumors.
Continued strong performance in the third quarter of 2023 – Biotech Investments
EQS-News: SYNLAB AG / Key word(s): Quarter Results Continued strong performance in the third quarter of 2023 08.11.2023 / 07:30 CET/CEST The issuer is solely